Loading...

IMNN IMUNON INC Operational Disruptions 8-K Filing

MNN

MNN

IMUNON INC

(IMNN)

2024 8-K

Show Summary

Show Summary

Compliance Issues

Voluntary Delisting

Equity Offerings

Primary Offerings

Failure to Meet Listing Sta...

Warrant Exchange

Financial Statements

FDA Study Design

Financial Results

New CMO Appointment

Q3 2024 Results

Management Change

Sales Agreement Termination

Q2 2024 Results

Securities Purchase Agreement

Positive Trial Data Announc...

Annual Meeting Results

Retirement of CFO and Appoi...

Appointment of CEO

Compliance regained with Na...

Amendments to Bylaws

Resignation of CEO

Appointment of Dr. Sébastie...

Annual Meeting Approval

Departure of Directors

Restated Certificate of Inc...

Departure of Officer

Departure of Directors

External Links:

Imunon, Inc. announced positive topline data from its Phase 2 OVATION 2 trial of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy in patients with advanced ovarian cancer.

AI Assistant

IMUNON INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.